Hyperleukotrieneuria in patients with allergic and inflammatory disease

Allergology International

Volumn 57, Issue 4, 2008, Pages 313-320

  Taniguchi, Masami ^a   Higashi, Noritaka ^a   Ono, Emiko ^a   Mita, Haruhisa ^a   Akiyama, Kazuo ^a  

^a SAGAMIHARA NATIONAL HOSPITAL   (Japan)

Author keywords

Anaphylaxis; Aspirin intolerant ashtma (AIA); Church Strauss syndrome (CSS); Cysteinyl leukotrienes (CysLTs); Nasal polyp

Indexed keywords

LEUKOTRIENE E4; PEPTIDOLEUKOTRIENE;

ALLERGIC ASTHMA; ALLERGY; ANAPHYLAXIS; ASPIRIN INTOLERANT ASTHMA; ASTHMA; CHURG STRAUSS SYNDROME; HAY FEVER; HUMAN; HYPERLEUKOTRIENEURIA; INFLAMMATORY DISEASE; LEUKOCYTE MIGRATION; LIPOGENESIS; LOEFFLER PNEUMONIA; METABOLIC DISORDER; NOSE POLYP; PRIORITY JOURNAL; REVIEW; RISK FACTOR; URINARY EXCRETION; URINE LEVEL; VASCULITIS;

EID: 59549089688     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.08-RAI-0040     Document Type: Review

References (41)

1. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
2. Dahlen SE. Lipid mediator pathways in the lung: leukotrienes as a new target for the treatment of asthma. Clin Exp Allergy 1998; 28(Suppl 5):141-6.
3. Wenzel SE. The role of leukotrienes in asthma. Prostaglandins Leukot Essent Fatty Acids 2003;69:145-55.
4. Drazen JM. Leukotrienes in asthma. Adv Exp Med Biol 2003; 525:1-5.
5. Zakrzewski JT, Sampson AP, Evans JM, Barnes NC, Piper PJ, Costello JF. The biotransformation in vitro of cysteinyl leukotrienes in blood of normal and asthmatic subjects. Prostaglandins 1989; 37:425-44.
6. Dahlen SE, Kumlin M. Can asthma be studied in the urine? Clin Exp Allergy 1998;28:129-33.
7. Mita H, Oosaki R, Mizushima Y, Kobayashi M, Akiyama K. Efficient method for the quantitation of urinary leukotriene E4: extraction using an Empore C18 disk cartridge. J Chromatogr B Biomed Sci Appl 1997; 692:461-6.
8. Asano K, Lilly CM, O'Donnell WJ et al. Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J Allergy Clin Immunol 1995;96:643-51.
9. Smith CM, Hawksworth RJ, Thien FC, Christie PE, Lee TH. Urinary leukotriene E4 in bronchial asthma. Eur Respir J 1992; 5:693-9.
10. Oosaki R, Mizushima Y, Mita H, Shida T, Akiyama K, Kobayashi M. Urinary leukotriene E 4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma. Allergy 1997;52:470-3.
11. Higashi N, Taniguchi M, Mita H et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2004;113:227-83.
12. Kawagishi Y, Mita H, Taniguchi M et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002; 109:936-42.
13. Taniguchi M, Tsurikisawa N, Higashi N et al. Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int 2007; 56:97-103.
14. Higashi N, Mita H, Taniguchi M et al. Urinary eicosanoid and tyrosine derivative concentration in patients with vasculitides. J Allergy Clin Immunol 2004;114:1353-8.
15. Oosaki R, Mizushima Y, Kawasaki A et al. Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in patients with spontaneous asthma attacks. Int Arch Allergy Immunol 1997;114:373-8.
16. Oosaki R, Mizushima Y, Kawasaki A, Mita H, Akiyama K, Kobayashi M. Correlation among urinary eosinophil protein X, leukotriene E4, and 11-dehydrothromboxane B2 in patients with spontaneous asthmatic attack. Clin Exp Allergy 1998;28:1138-44.
17. Green SA, Malice MP, Tanaka W, Tozzi CA, Reiss TF. Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax 2004; 59:100-4.
18. Tanaka S, Tanaka H, Abe S. High dose of inhaled fluticasone reduces high levels of urinary leukotriene E4 in the early morning in mild and moderate nocturnal asthma. Chest 2003;124:1768-73.
19. Mita H, Turikisawa N, Yamada T, Taniguchi M. Quantification of leukotriene B4 glucuronide in human urine. Prostaglandins Other Lipid Mediat 2007;83:42-9.
20. O'Sullivan S, Roquet A, Dahlén B, Dahlén S, Kumlin M. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. Clin Exp Allergy 1998; 28:1332-9.
21. Ono E, Mita H, Taniguchi M et al. Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation. J Allergy Clin Immunol. Epub 2008 Jul 10.
22. 2 in vivo. Thorax 2004;59:453-5.
23. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289-97.
24. Okuda M, Watase T, Mezawa A, Liu CM. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537-40.
25. Naclerio RM, Baroody FM, Togias AG. The role of leukotrienes in allergic rhinitis: a review. Am Rev Respir Dis 1991;143:S91-5.
26. Higashi N, Taniguchi M, Mita H, Ishii T, Akiyama K. Nasal blockage and urinary leukotriene E4 concentration in patients with seasonal allergic rhinitis. Allergy 2003;58: 476-80.
27. Slavin RG, Spector SL, Bernstein IL et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005;116(6 Suppl):S13-47.
28. Steinke JW, Bradley D, Arango P et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol 2003; 111:342-9.
29. Perez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 2005;115:1189-96.
30. Taniguchi M, Higashi N, Ishii T, Yamamoto K, Mita H, Akiyama K. Role of cysteinyl-leukotrienes in the pathogenesis of nasal polyposis in patients with asthma. Inflammation and Regeneration 2007; 27:565-9.
31. Nagata M, Saito K. The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways. Int Arch Allergy Immunol 2003;131(Suppl 1):7-10.
32. 4 as an eosinophil chemoattractant. Drugs Exp Clin Res 1991; 17:543-8.
33. Panettieri RA. Cellular and molecular mechanisms regulating airway smooth muscle proliferation and cell adhesion molecule expression. Am J Respir Crit Care Med 1998;158:S133-40.
34. The diagnosis and management of anaphylaxis: An updated practice parameter. J Allergy Clin Immunol 2005; 115:483-453.
35. Simons FE, Frew AJ, Ansotegui IJ et al. Risk assessment in anaphylaxis: Current and future approaches. J Allergy Clin Immunol 2007;120 (1 Suppl):S2-24.
36. Ono E, Taniguchi M, Mita H, Akiyama K. Salicylamide-induced anaphylaxis: increased urinary leukotriene E4 and prostaglandin D2 metabolite. Allergy 2008;63:480-2.
37. Ono E, Taniguchi M, Mita H et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy 2008;(in press).
38. Cottin V, Cordier JF. Eosinophilic pneumonias. Allergy 2005; 60:841-57.
39. Allen J, Davis W. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994;150:1423-38.
40. Carrington C, Addington WW, Groff AM et al. Chronic eosinophilic pneumonia. N Engl J Med 1969;280:787-98.
41. Ono E, Taniguchi M, Mita H et al. Increased urinary leukotriene E4 concentration in patients with eosinophilic pneumonia. Eur Respir J 2008;32:437-42.